Swiss National Bank Has $108.62 Million Position in Regeneron Pharmaceuticals Inc (REGN)
Swiss National Bank lifted its position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 0.1% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 288,900 shares of the biopharmaceutical company’s stock after acquiring an additional 400 shares during the period. Swiss National Bank’s holdings in Regeneron Pharmaceuticals were worth $108,615,000 as of its most recent SEC filing.
Several other large investors have also recently added to or reduced their stakes in REGN. Ark Investment Management LLC grew its stake in shares of Regeneron Pharmaceuticals by 78.8% in the second quarter. Ark Investment Management LLC now owns 1,234 shares of the biopharmaceutical company’s stock valued at $606,000 after buying an additional 544 shares in the last quarter. Virtu KCG Holdings LLC bought a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at $206,000. AHL Partners LLP bought a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at $1,544,000. Cubist Systematic Strategies LLC grew its stake in shares of Regeneron Pharmaceuticals by 176.1% in the second quarter. Cubist Systematic Strategies LLC now owns 671 shares of the biopharmaceutical company’s stock valued at $330,000 after buying an additional 428 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. grew its stake in shares of Regeneron Pharmaceuticals by 13.3% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 3,212 shares of the biopharmaceutical company’s stock valued at $1,578,000 after buying an additional 378 shares in the last quarter. 65.89% of the stock is owned by institutional investors and hedge funds.
Several research firms recently weighed in on REGN. BTIG Research reissued a “buy” rating and issued a $520.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, November 22nd. BMO Capital Markets set a $444.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a “hold” rating in a research report on Monday, November 27th. Citigroup cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $480.00 to $380.00 in a research report on Friday, December 1st. Cowen reaffirmed a “hold” rating and set a $450.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, February 7th. Finally, Leerink Swann reduced their price objective on shares of Regeneron Pharmaceuticals from $568.00 to $502.00 and set an “outperform” rating for the company in a research report on Friday. Four investment analysts have rated the stock with a sell rating, fourteen have given a hold rating and eleven have given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $463.19.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $4.18 by $1.05. The company had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.50 billion. Regeneron Pharmaceuticals had a net margin of 20.41% and a return on equity of 28.48%. Regeneron Pharmaceuticals’s quarterly revenue was up 28.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.04 earnings per share. sell-side analysts forecast that Regeneron Pharmaceuticals Inc will post 14.13 EPS for the current year.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.